Formycon AG 0W4N.L Stock
Formycon AG Price Chart
Formycon AG 0W4N.L Financial and Trading Overview
| Formycon AG stock price | 42.05 EUR |
| Previous Close | 67.5 EUR |
| Open | 67.85 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 67.85 - 67.85 EUR |
| 52 Week Range | 64.8 - 91.86 EUR |
| Volume | 1.27K EUR |
| Avg. Volume | 1.48K EUR |
| Market Cap | 5.71M EUR |
| Beta (5Y Monthly) | 0.95977 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.218 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0W4N.L Valuation Measures
| Enterprise Value | 1.08B EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.13435228 |
| Price/Book (mrq) | 2.8785594 |
| Enterprise Value/Revenue | 25.348 |
| Enterprise Value/EBITDA | -63.284 |
Trading Information
Formycon AG Stock Price History
| Beta (5Y Monthly) | 0.95977 |
| 52-Week Change | -8.46% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 91.86 EUR |
| 52 Week Low | 64.8 EUR |
| 50-Day Moving Average | 70.86 EUR |
| 200-Day Moving Average | 76.44 EUR |
0W4N.L Share Statistics
| Avg. Volume (3 month) | 1.48K EUR |
| Avg. Daily Volume (10-Days) | 490 EUR |
| Shares Outstanding | 9.34M |
| Float | 10.08M |
| Short Ratio | N/A |
| % Held by Insiders | 51.77% |
| % Held by Institutions | 9.04% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 84.69% |
| Operating Margin (ttm) | -41.71% |
| Gross Margin | 28.40% |
| EBITDA Margin | -40.054% |
Management Effectiveness
| Return on Assets (ttm) | -2.39% |
| Return on Equity (ttm) | 17.45% |
Income Statement
| Revenue (ttm) | 42.5M EUR |
| Revenue Per Share (ttm) | 3.1 EUR |
| Quarterly Revenue Growth (yoy) | 50.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -17022000 EUR |
| Net Income Avi to Common (ttm) | 35.99M EUR |
| Diluted EPS (ttm) | -1.218 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 9.82M EUR |
| Total Cash Per Share (mrq) | 0.65 EUR |
| Total Debt (mrq) | 49.31M EUR |
| Total Debt/Equity (mrq) | 13.83 EUR |
| Current Ratio (mrq) | 0.602 |
| Book Value Per Share (mrq) | 23.57 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18878000 EUR |
| Levered Free Cash Flow (ttm) | -23878124 EUR |
Profile of Formycon AG
| Country | United Kingdom |
| State | N/A |
| City | Planegg |
| Address | Fraunhoferstrasse 15 |
| ZIP | 82152 |
| Phone | 49 89 864 667 100 |
| Website | https://www.formycon.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 137 |
Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Q&A For Formycon AG Stock
What is a current 0W4N.L stock price?
Formycon AG 0W4N.L stock price today per share is 42.05 EUR.
How to purchase Formycon AG stock?
You can buy 0W4N.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Formycon AG?
The stock symbol or ticker of Formycon AG is 0W4N.L.
How many shares does Formycon AG have in circulation?
The max supply of Formycon AG shares is 84.15K.
What is Formycon AG Price to Earnings Ratio (PE Ratio)?
Formycon AG PE Ratio is now.
What was Formycon AG earnings per share over the trailing 12 months (TTM)?
Formycon AG EPS is -1.218 EUR over the trailing 12 months.